Lyka Labs (BOM:500259) Cyclically Adjusted Revenue per Share: ₹44.36 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500259 Lyka Labs Ltd BOM:500259
59 GF Score
Price ₹80.86
GF Value ₹129.78
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lyka Labs Cyclically Adjusted Revenue per Share?

Lyka Labs BOM:500259 -2.00% 59 Cyclically Adjusted Revenue per Share is ₹44.36 as of Jun. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 59/100 and a GF Value™ of ₹129.78 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lyka Labs's adjusted revenue per share for the three months ended in Jun. 2026 was ₹11.703. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹44.36 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Lyka Labs's average Cyclically Adjusted Revenue Growth Rate was -3.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lyka Labs was -6.20% per year. The lowest was -6.20% per year. And the median was -6.20% per year.

As of today (2026-09-16), Lyka Labs's current stock price is ₹80.86. Lyka Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹44.36. Lyka Labs's Cyclically Adjusted PS Ratio of today is 1.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lyka Labs was 2.92. The lowest was 0.86. And the median was 1.85.


Lyka Labs  (BOM:500259) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lyka Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=80.86/44.356
=1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lyka Labs was 2.92. The lowest was 0.86. And the median was 1.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lyka Labs Cyclically Adjusted Revenue per Share Related Terms


Lyka Labs Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lyka Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs Cyclically Adjusted Revenue per Share Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 47.30 43.54

Lyka Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.96 48.72 49.02 43.54 44.36

BOM:500259 vs VRTX, REGN, MRNA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Lyka Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Cyclically Adjusted PS Ratio falls into.


BOM:500259
59GF Score
Lyka Labs Ltd BOM:500259
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lyka Labs's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.703/167.3573*167.3573
=11.703

Current CPI (Jun. 2026) = 167.3573.

Lyka Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 18.971 99.841 31.800
201512 13.445 102.901 21.867
201603 14.852 102.518 24.245
201606 9.099 105.961 14.371
201609 13.651 105.961 21.561
201612 11.639 105.196 18.517
201703 13.885 105.196 22.090
201803 0.000 109.786 0.000
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201906 5.105 120.880 7.068
201909 4.748 123.175 6.451
201912 6.399 126.235 8.484
202003 5.253 124.705 7.050
202006 6.176 127.000 8.139
202009 6.084 130.118 7.825
202012 9.346 130.889 11.950
202103 8.457 131.771 10.741
202106 17.231 134.084 21.507
202109 25.754 135.847 31.728
202112 12.399 138.161 15.019
202203 12.263 138.822 14.784
202206 9.582 142.347 11.266
202209 8.897 144.661 10.293
202212 6.210 145.763 7.130
202303 7.246 146.865 8.257
202306 7.061 150.280 7.863
202309 8.458 151.492 9.344
202312 9.841 152.924 10.770
202403 8.391 153.035 9.176
202406 8.438 155.789 9.065
202409 11.531 157.882 12.223
202412 9.470 158.323 10.010
202503 9.366 157.552 9.949
202506 9.253 159.755 9.693
202509 10.272 162.289 10.593
202512 8.610 163.281 8.825
202603 7.854 164.272 8.001
202606 11.703 167.357 11.703

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹44.36 mean?
Lyka Labs (BOM:500259) has a Cyclically Adjusted Revenue per Share of ₹44.36 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lyka Labs and its competitors.
Is Lyka Labs' Cyclically Adjusted Revenue per Share too high?
Lyka Labs' current Cyclically Adjusted Revenue per Share is ₹44.36. Overall, Lyka Labs has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Lyka Labs' Cyclically Adjusted Revenue per Share of ₹44.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lyka Labs and its competitors. Lyka Labs's current Cyclically Adjusted Revenue per Share is ₹44.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹129.78, compared to a current price of ₹80.86 — trading 37.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹44.36. Lyka Labs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Cyclically Adjusted Revenue per Share is ₹44.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹80.86 is trading 37.7% below its estimated GF Value™ of ₹129.78. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • Cyclically Adjusted Revenue per Share: ₹44.36
  • GF Value™: ₹129.78 vs. price of ₹80.86 (37.7% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
59GF Score

Get the complete analysis for BOM:500259

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹80.86
Price
₹129.78
GF Value